Captek Softgel International acquires J+D Labs
J+D Labs’ extensive experience manufacturing a wide-range of softgels, specialized tablets, capsules, and powder formulations complements Captek’s offerings.
California-based Captek Softgel International (CSI) has acquired J+D Labs Pharma Manufacturing. CSI is a portfolio company of Swander Pace Capital (SPC), and the acquisition of J+D Labs is a continuation of SPC’s focus on investing in and growing industry-leading vitamin, mineral, and supplement companies.
For decades J+D Labs has been well recognized in the nutraceutical industry as a first-class manufacturer of health and wellness supplements producing more than 1,000 unique formulations. More recently J+D Labs has brought NutraStock to the market, more than 250 bulk stock dietary supplements manufactured in the US.
Captek CEO David Wood said this union will result in a greater diversity of offerings and services within the supplement channel. “We have long regarded J+D Labs’ reputation and the significance of what they bring to the table as a leader in the industry,” he said. J+D Labs’ extensive experience manufacturing a wide-range of softgels, specialized tablets, capsules, and powder formulations was a perfect complement to Captek’s offerings. Wood stated, “Going forward, we are committed to our collective success through focusing on our customers, sharing best practices, and continuing our best-in-class quality and compliance standards.”
“This acquisition is positive for everyone: for our employees, our suppliers, our customers, and the end-users,” said J+D Labs owner, Jay Majmudar. CSI is well established in more than 20 countries. “We are happy to play a key role in helping to expand distribution even further. We will continue to make quality, price, and timely delivery a top priority,” emphasized Majmudar.
The newly joined companies will continue to produce high quality products in both Cerritos and Vista, CA. This will give customers the business continuity planning they have long sought by having the ability to have their products manufactured at either site. As a result, more than 300,000 sq ft of manufacturing, warehousing, and analytical testing labs will immediately bring to market greater capacity, expertise, comprehensive turnkey packaging, the benefits of enteric coating, and more.
In the coming months the combined company will work with its customer-facing teams to communicate its newly expanded product and service offerings to both existing and prospective customers.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance